Why the study?
Do beta-blockers, including nebivolol, improve clinical outcomes and hemodynamics in patients with chronic heart failure?
Do beta-blockers, including nebivolol, improve clinical outcomes and hemodynamics in patients with chronic heart failure?
Beta-blockers, including nebivolol, are effective in managing chronic heart failure by improving hemodynamics and symptoms while reducing mortality and hospitalizations.
There were presented results of clinical trials on β-adrenoblockers usage in patients with chronic heart failure (CHF) as well as data of own study on nebivolol efficacy and tolerability in 113 patients with ischemic heart disease, complicated with CHF. It is emphasized that therapy with β-adrenoblockers positively influences on cardiac hemodynamics and CHF symptoms, significantly reduces mortality risk and the frequency of hospitalizations. The usage of β-adrenoblockers is indicated in CHF of any stage. Efficacy of metoprolol, bisoprolol and carvedilol had been proven in CHF therapy. Nebivolol was effective in elderly patients with CHF.
No takes yet. Share an insight, caveat, or question.
A 2007 study studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: